| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5712 | 2021 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1424 | 2021 |
| Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. P Braitstein, MW Brinkhof, F Dabis, M Schechter, A Boulle, P Miotti, ... Lancet (London, England) 367 (9513), 817-824, 2006 | 1357 | 2006 |
| Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 … VC Marconi, AV Ramanan, S de Bono, CE Kartman, V Krishnan, R Liao, ... The lancet Respiratory medicine 9 (12), 1407-1418, 2021 | 740 | 2021 |
| Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries MWG Brinkhof, F Dabis, L Myer, DR Bangsberg, A Boulle, D Nash, ... Bulletin of the World Health Organization 86 (7), 559-567, 2008 | 442 | 2008 |
| Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration P Braitstein, A Boulle, D Nash, MWG Brinkhof, F Dabis, C Laurent, ... Journal of women's health 17 (1), 47-55, 2008 | 243 | 2008 |
| Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies D Nash, M Katyal, MWG Brinkhof, O Keiser, M May, R Hughes, F Dabis, ... Aids 22 (17), 2291-2302, 2008 | 234 | 2008 |
| Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy L Terry, E Sprinz, R Stein, NB Medeiros, J Oliveira, JP Ribeiro Medicine & Science in Sports & Exercise 38 (3), 411-417, 2006 | 187 | 2006 |
| Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring ART-LINC of IeDEA Study Group Aids 23 (14), 1867-1874, 2009 | 186 | 2009 |
| O conhecimento de HIV/aids na terceira idade: estudo epidemiológico no Vale do Sinos, Rio Grande do Sul, Brasil AR Lazzarotto, AS Kramer, M Hädrich, M Tonin, P Caputo, E Sprinz Ciência & Saúde Coletiva 13, 1833-1840, 2008 | 169 | 2008 |
| Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: a cross-sectional study RA Maciel, HM Klück, M Durand, E Sprinz International Journal of Infectious Diseases 70, 30-35, 2018 | 159 | 2018 |
| Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral … SH Tuboi, MWG Brinkhof, M Egger, RA Stone, P Braitstein, D Nash, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 45 (1), 52-59, 2007 | 146 | 2007 |
| Oxford COVID Vaccine Trial Group Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... Lancet 397 (10269), 99-111, 2021 | 145 | 2021 |
| Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy O Keiser, P MacPhail, A Boulle, R Wood, M Schechter, F Dabis, E Sprinz, ... Tropical Medicine & International Health 14 (10), 1220-1225, 2009 | 117 | 2009 |
| Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil SH Tuboi, LH Harrison, E Sprinz, RKM Albernaz, M Schechter JAIDS Journal of Acquired Immune Deficiency Syndromes 40 (3), 324-328, 2005 | 113 | 2005 |
| Moderate and high intensity exercise training in HIV-1 seropositive individuals: a randomized trial L Terry, E Sprinz, JP Ribeiro International journal of sports medicine 20 (02), 142-146, 1999 | 111 | 1999 |
| Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1–infected individuals: a randomized trial RK Lazzaretti, R Kuhmmer, E Sprinz, CA Polanczyk, JP Ribeiro Journal of the American College of Cardiology 59 (11), 979-988, 2012 | 110 | 2012 |
| Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial L Bravo, I Smolenov, HH Han, P Li, R Hosain, F Rockhold, SAC Clemens, ... The lancet 399 (10323), 461-472, 2022 | 105 | 2022 |
| Characterization of a new circulating recombinant form comprising HIV-1 subtypes C and B in southern Brazil AF Santos, TM Sousa, EAJM Soares, S Sanabani, AMB Martinez, ... Aids 20 (16), 2011-2019, 2006 | 105 | 2006 |
| HIV/AIDS e treinamento concorrente: a revisão sistemática AR Lazzarotto, LF Deresz, E Sprinz Revista Brasileira de Medicina do Esporte 16, 149-154, 2010 | 101 | 2010 |
